Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Organon's Ending Cash Position for the quarter that ended in Mar. 2026 was MXN20,124 Mil.
Organon's quarterly Ending Cash Position
declined
from Sep. 2025 (MXN12,327 Mil) to Dec. 2025 (MXN10,335 Mil) but then
increased
from Dec. 2025 (MXN10,335 Mil) to Mar. 2026 (MXN20,124 Mil).
Organon's annual Ending Cash Position
increased
from Dec. 2023 (MXN11,763 Mil) to Dec. 2024 (MXN14,078 Mil) but then
declined
from Dec. 2024 (MXN14,078 Mil) to Dec. 2025 (MXN10,335 Mil).
Organon Ending Cash Position Related Terms
Organon Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Organon's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Organon's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN20,124 Mil mean?
Organon (MEX:OGN) has a Ending Cash Position of MXN20,124 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Organon and its competitors.
Is Organon's Ending Cash Position too high?
Organon's current Ending Cash Position is MXN20,124 Mil. Overall, Organon has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organon's Ending Cash Position compare to AMRN and SCLX?
Organon's Ending Cash Position of MXN20,124 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Organon and its competitors. Organon's current Ending Cash Position is MXN20,124 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (MEX:OGN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN266.91, compared to a current price of MXN225.00 — trading 15.7% below its estimated fair value. The current Ending Cash Position is MXN20,124 Mil. Organon's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Organon (MEX:OGN), the current Ending Cash Position is MXN20,124 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (MEX:OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of MXN225.00 is trading 15.7% below its estimated GF Value™ of MXN266.91.
GuruFocus considers Organon to be Modestly Undervalued.
Key valuation signals for MEX:OGN:
Ending Cash Position: MXN20,124 Mil
GF Value™: MXN266.91 vs. price of MXN225.00 (15.7% below fair value)
No single metric tells the full story. See the MEX:OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
60GF Score
Get the complete analysis for MEX:OGN
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OGN has been successfully added to your 
